Search Follow us

 

We are re-initiating coverage on Bionomics, a pharmaceutical company developing drugs for neuropsychiatric indications and oncology. It has leveraged its ionX and MultiCore development platforms to identify BNC210, a drug with a novel anxiolytic mechanism currently in Phase IIb for post-traumatic stress disorder (PTSD). It has also leveraged this platform with partner Merck to target cognitive dysfunction associated with Alzheimer’s disease, in a deal worth US$506m in milestones plus royalties. We re-initiate with a valuation of A$418.7m or A$0.87 per share.

Continue reading

This version is programmatically created by Responsive Labs and qualified in its entirety to the original PDF.

Powered by Responsive Labs